Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo.
about
Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinomaTrastuzumab in the management of gastroesophageal cancer: patient selection and perspectivesAntiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer.Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis.Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway.Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.The potential role of immunotherapy to treat colorectal cancer.Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints.Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma.Immunotherapy for gastric cancers: emerging role and future perspectives.Checkpoint inhibition for colorectal cancer: progress and possibilities.Immunotherapy for oesophagogastric cancer.Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.Strategies targeting angiogenesis in advanced non-small cell lung cancer.Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?Angiogenesis inhibitors in early development for gastric cancer.First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma.Newly developed anti-angiogenic therapy in non-small cell lung cancer.Immune-Mediated and Hypoxia-Regulated Programs: Accomplices in Resistance to Anti-angiogenic Therapies.Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma.Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Immunotherapeutic interventions of Triple Negative Breast Cancer.
P2860
Q26741530-5097E564-3D99-4845-A258-3CE042234BDAQ28077666-09BEE438-CB7A-4DE3-9597-2E46E74A680DQ30399006-7487A392-F71A-41BD-B668-9EF11BDDAD1BQ35294099-0ECC08F8-0B55-4EA6-BEAB-0180F9272278Q36831553-BDA2A1A1-A9B8-4215-A18F-7E4DE87A0749Q37392642-76108432-2A40-48DF-898B-2028008068C7Q37686978-117AB0FE-BF5E-4EB1-9AD7-CB39AAB34E3DQ37741143-8EE1B05A-836D-4F09-A7F2-1931095AF8FEQ38292169-E611EFD9-62C4-409B-A735-510B4330183FQ38728953-95347BC6-4024-49AB-B188-6011DA6DC1EBQ38735118-A9F32F19-0BA4-461A-9927-F493C3EA63C2Q38737954-C7B3D285-F965-49B0-96E3-46BA5A7EA53CQ38738652-8772A899-0E3D-465C-B8EE-036A2D4A0FF5Q38838641-50C6CFE7-EC69-407A-8304-273BEBAC9E12Q38842511-A49521E4-AA71-484C-83EA-2EE3FB044E99Q39067386-D36FC807-24A9-43CF-BBF7-CD7AA88957E2Q39402079-77C8DE77-F52D-402F-9A83-1051E9680F2FQ41593429-3D82CC32-7CBD-44FB-9397-CB129A43C32FQ47136084-3E48EECF-D28A-4A5B-BDC1-604D032EC53AQ47996955-938097DF-7EC5-4CB4-BA74-C3516DF64C32Q52576596-59801014-8CE8-4CFF-B68A-ED4C424A4BF9Q52668159-7DCF5AD6-FAE7-4794-BA95-BFF93E1B1575Q53743967-80B45767-356A-4C00-B716-1310FAC3FD14Q54966706-C1CBD2C8-8293-4635-9C1E-E6A81A015A58Q55190117-B2110B66-9A8D-40A4-B82A-437F5D9139F7Q55257180-C0FB0560-FE2E-43D3-A464-986439B8EE77
P2860
Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Simultaneous blockade of progr ...... ic anti-tumour effect in vivo.
@en
Simultaneous blockade of progr ...... elial growth factor receptor 2
@nl
type
label
Simultaneous blockade of progr ...... ic anti-tumour effect in vivo.
@en
Simultaneous blockade of progr ...... elial growth factor receptor 2
@nl
prefLabel
Simultaneous blockade of progr ...... ic anti-tumour effect in vivo.
@en
Simultaneous blockade of progr ...... elial growth factor receptor 2
@nl
P2093
P2860
P356
P1476
Simultaneous blockade of progr ...... ic anti-tumour effect in vivo.
@en
P2093
K Wakatsuki
S Nishiwada
Y Nakajima
P2860
P304
P356
10.1111/CEI.12069
P577
2013-06-01T00:00:00Z